Health

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25, 2025, the proportion of own shares held by…

9 months ago

Theratechnologies to Announce Second Quarter 2025 Financial Results

MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical…

9 months ago

Theratechnologies enters into Definitive Agreement to be Acquired by CBBiotechnology, an Affiliate of Future Pak

Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per…

9 months ago

Range Impact Announces Expansion of Investment in its Fola Mine Complex with Acquisition of Two Mining Permits and Two Coal Leases

CLEVELAND, OHIO, July 02, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public…

9 months ago

Raw Garden Announces California Cannabis Deals for July 4th to 7/10

SANTA YNEZ, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Raw Garden, California’s leading Clean Green-certified cannabis concentrates brand, marks its…

9 months ago

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

July 02, 2025 03:00 ET  | Source: Belite Bio, Inc -  500 subjects enrolled across the United States, the United…

9 months ago

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch Comprehensive clinical performance study encompassed 646…

9 months ago

OSE Immunotherapeutics met jour linformation sur les procdures en cours

OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2, 2025, 8 AM – OSE Immunotherapeutics SA (ISIN:…

9 months ago

Processa Pharmaceuticals Provides Portfolio and Business Update

Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Continue enrolling patients in Phase 2 study of…

9 months ago

Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis

July 01, 2025 09:00 ET  | Source: Inmagene Biopharmaceuticals The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007…

9 months ago